Eterna Therapeutics
ERNA
11 hedge funds and large institutions have $712K invested in Eterna Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
15% less funds holding
Funds holding: 13 → 11 (-2)
27% less capital invested
Capital invested by funds: $982K → $712K (-$270K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.26K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.26K |
| 3 |
MA
Montag & Associates
Atlanta,
Georgia
|
+$752 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.1K |
| 2 |
Renaissance Technologies
New York
|
-$24K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.78K |
| 4 |
BlackRock
New York
|
-$1.5K |
| 5 |
NS
NBC Securities
Birmingham,
Alabama
|
-$1K |
ERNA Hedge Fund Activity: Q2 2024 in Review
11 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2024, worth a combined $712K — down 27% from $982K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ERNA and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $2.26K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24.1K sold.
- 11 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2024, down from 13 in Q1 2024.
- Funds reported $712K of Eterna Therapeutics stock for Q2 2024, down 27% quarter-over-quarter.
- 1 fund opened new Eterna Therapeutics positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Eterna Therapeutics buyer in Q2 2024 was Geode Capital Management, an estimated $2.26K added.
- The largest Eterna Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $24.1K sold.
Based on aggregated 13F filings for Q2 2024.